News14-JUN-10
Meeting our client partner’s commercial need for additional sachet capacity, Almac completes a £2 million investment programme. Almac Pharma Services have today announced the completion of a client sponsored capital investment of £2 million at the company’s commercial facilities at the Group’s headquarters in The new facility, at approximately five and half thousand square feet, includes dispensing and blending suites to accommodate 2.5 tonne batches, coupled to a state of the art sachet filling and packaging line. Supporting storage and wash areas complete the new facility. Annualised output will be in excess of 120 million sachets, split across various packed formats. Geoff Sloan, VP Manufacturing Operations of Almac Pharma Services said: “This investment has allowed our client to quickly meet growing demand for one of their key future products. Utilising Almac’s technical and project management expertise to deliver a complex engineering solution to an aggressive project timeline will assist our client in securing the market for this strongly performing product.” Graeme McBurney, President and M.D of Almac Pharma Services said: “This level of investment demonstrates our commitment to building long term, strategic relationships with our client partners.” -End- Contact Tania Davis Almac Pharma Services Tel: +44 2838 363363 Tristan Jervis DeFacto Tel: + 44 2078 613019 About Almac Group The Almac Group comprises five closely integrated divisions offering a broad range of services from R&D, translational genomic services, API manufacture, formulation development, clinical trial supply and technology (IVRS & Web), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors. The company employs over 2,600 individuals and is headquartered in For more information about the Almac Group, please visit www.almacgroup.com or e-mail info@almacgroup.com |
Latest News
RSS
Almac wins UK Great Place to Work award |